4D Molecular Therapeutics, Inc. (FDMT) compared with its closest peers (CADL, AURA, ALLO, TECX, PRME). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $944.24M | -7.8 |
| Aura Biosciences, Inc. (AURA) | $804.23M | -3.1 |
| Allogene Therapeutics, Inc. (ALLO) | $721.37M | -1.6 |
| Tectonic Therapeutic, Inc. (TECX) | $678.35M | -5.1 |
| Prime Medicine, Inc. (PRME) | $583.39M | -2.6 |
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $582.00M | — |
| REGENXBIO Inc. (RGNX) | $571.26M | -3.8 |
| Zura Bio Limited (ZURA) | $545.29M | -4.9 |
| Artiva Biotherapeutics, Inc. (ARTV) | $543.66M | -1.2 |
| C4 Therapeutics, Inc. (CCCC) | $494.56M | -1.5 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
FDMT overview · FDMT earnings · FDMT financials · FDMT KPIs · FDMT investor relations · FDMT ownership · FDMT filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.